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Abstract Group IIA secreted phospholipase A2 (sPLA2-IIA) is
the most abundant element in human tissues of a large family of
low molecular weight phospholipases A2, which shows properties
di¡erent from those displayed by the cytosolic phospholipase A2
involved in the release of arachidonic acid. sPLA2-IIA behaves
as a ligand for a group of receptors inside the C-type multilectin
mannose receptor family and also interacts with heparan sulfate
proteoglycans such as glypican, the dermatan/chondroitin sul-
fate-rich decorin, and the chondroitin sulfate-rich versican,
thus being able to internalize to speci¢c compartments within
the cell and producing biological responses. This review provides
a short summary of the biological actions of sPLA2-IIA on
intracellular signaling pathways.
' 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Secreted phospholipases A2 and cytosolic phospholipase A2
Phospholipases A2 (PLA2) are a large family of related
enzymes that have been classi¢ed into groups I^XII according
to several criteria which include catalysis of the hydrolysis of
the sn-2 ester bond of glycerophospholipids, complete protein
sequence, existence of homologous enzymes, and ¢nding of
active splice variants [1^4]. Group I, II, V, and X PLA2 are
closely related enzymes, which can be collectively termed se-
creted phospholipases (sPL), are characterized by a low mo-
lecular mass of 13^18 kDa, several disul¢de bonds, a require-
ment for millimolar amounts of Ca2þ for catalytic activity,
and a low selectivity for phospholipids with di¡erent polar
heads and fatty acids. They share a common mechanism for
cleaving the sn-2 ester bond of phospholipids, involving a
catalytic histidine, but show a di¡erent pattern of expression
among the di¡erent tissues. Thus, group IIE PLA2 has been
detected in human brain, lung and placenta [5]. Group V
sPLA2 is expressed in human heart and, less abundantly, in
lung [6], and group X sPLA2 is expressed in spleen, thymus
and blood leukocytes [7].
Group IIA PLA2 (also known as in£ammatory PLA2,
sPLA2-IIA) has been considered the main human element of
the large family of sPLA2 for several reasons: (i) its early
characterization as a secreted enzyme from synovial £uid
[8,9] ; (ii) its broad expression pattern in human tissues as
compared to other elements of group II enzymes [5]; (iii)
the induction of its synthesis by endotoxin and cytokines via
paracrine and/or autocrine processes during in£ammatory
processes of clinical relevance, which have allowed the char-
acterization of this enzyme as a newly recognized acute phase
protein [10] ; (iv) its potent bactericidal e¡ects, which support
a role for this enzyme in the innate immunity against Staph-
ylococcus aureus infection [11]. In this connection, studies in-
tended to address the physiological relevance of sPLA2-IIA in
vivo have shown that its concentration in plasma may reach
V1 Wg/ml after injection of bacteria in experimental animals
[12], thus agreeing with the range of concentrations which
display antibacterial e¡ects in vitro [13,14].
At present, there are several ¢elds where the functional
relevance of sPLA2-IIA is a subject of active research, namely,
pathophysiological events in the neural system, and in£amma-
tory conditions such as arteriosclerosis, septic shock and rheu-
matoid arthritis. A relevant issue regarding its pathophysio-
logical potential has been provided by the evidence that many
of its biological actions depend on interactions with receptors
similar to those involved in the toxic e¡ects of PLA2 found in
venoms [15], and the ensuing e¡ects on signal transduction
pathways. This has prompted the appraisal of the pathways
through which sPLA2-IIA might exert its physiological func-
tions and distinct mechanisms have been proposed to explain
the signaling properties of sPLA2-IIA: (i) generation as a
result of its catalytic activity of both unesteri¢ed fatty acid
and lysophospholipid [16] ; (ii) perturbation of the cell mem-
brane by its interfacial interaction with substrate phospholip-
ids [17] ; (iii) interaction with membrane receptors analogous
to those binding other sPLA2 [18] ; (iv) binding to acceptor
proteoglycans such as the heparan sulfate-rich glypican [19],
the dermatan/chondroitin sulfate-rich decorin [20], and the
chondroitin sulfate-rich versican [21]. This is of interest, since
the aforementioned mechanisms of action can be cell-speci¢c,
thus leading to diverse biological e¡ects on di¡erent tissues.
For instance, interaction with the M-type receptor has been
proposed as the main mechanism of action explaining the
e¡ects of sPLA2-IIA in mast cells and macrophages [22^24],
but unlike mouse sPLA2-IIA, human sPLA2-IIA has not been
found to bind to the M-type receptor [25], thus making it
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likely that not all of the physiological receptors for sPLA2
have been characterized as yet. On the other hand, interaction
of sPLA2-IIA with decorin has been considered of relevance
to explain the e¡ect of sPLA2-IIA on atherogenesis, since this
would allow the modi¢cation of lipoproteins and the release
of lipid mediators at places of lipoprotein retention in the
arterial wall [20].
In contrast to sPLA2, the cytosolic PLA2 (cPLA2) is an
enzyme that hydrolyzes selectively arachidonic acid esteri¢ed
at the sn-2 position of phospholipids, has a molecular mass of
85 kDa and is regulated by a biochemical mechanism that
involves both docking to the cell membrane for access to
phospholipid substrate and phosphorylation-dependent acti-
vation by mitogen-activated protein (MAP) kinases [26,27].
The Ca2þ-dependent binding of cPLA2 to the membrane is
due to a C2 domain located at the N-terminus of the enzyme,
and this has been con¢rmed by mutation of the Ca2þ-binding
residues D43 and D93 of the C2 domain [28].
In this review, we focus on the biological e¡ects elicited by
sPLA2-IIA on 1321N1 astrocytoma cells and THP-1 mono-
cytes, taking advantage of the extensive work carried out in
these lines, and of the di¡erent physiological roles displayed
by these cell types. This allows us to summarize both the
connection of sPLA2-IIA with di¡erent signaling systems
and its potential pathogenetic role in some clinical conditions.
2. sPLA2-IIA elicits a mitogenic response and activates
arachidonic acid metabolism in astrocytoma cells
An important connection between sPLA2 and signal trans-
duction pathways emerged from the discovery that some
mammalian isoforms, including sPLA2-IIA, bind with high
a⁄nity to receptors ¢rst associated with the toxic e¡ect of
venom-secreted PLA2 [15], thus leading to mitotic prolifera-
tion, and disclosing a novel biological e¡ect of these enzymes
independent of their catalytic activity. The initial identi¢ca-
tion of sPLA2-binding proteins was carried out using a neuro-
toxic PLA2 extracted from the venom of the snake Oxyuranus
scutellatus scutellatus. Since the sPLA2-binding protein is most
abundant in brain, this ¢rst type of binding site was called the
N-type (neuronal-type) receptor [18]. A second type of recep-
tor for sPLA2-IIA was initially found in skeletal muscle, and
was termed the M-type (muscle-type) receptor [29]. Interest-
ingly, the M-type receptor has been intensively studied and
characterized as a member of a family of transmembrane pro-
teins with a structural organization similar to that of the
macrophage mannose receptor [29], thus making these recep-
tors to constitute a new group within the C-type multilectin
mannose receptor family [30]. Since a common property of
this protein family is endocytosis, it has been proposed that
the physiological role for the M-type sPLA2 receptor is to
internalize and deliver sPLA2-IIA to speci¢c compartments
within the cell where the enzyme might exert its activity.
The reports showing the existence of binding structures for
sPLA2-IIA in cell membranes have been complemented by
the description of the activation by sPLA2-IIA of intracellular
signaling pathways in di¡erent cell types, thus mimicking the
transducing mechanism conveyed by conventional stimuli act-
ing on membrane receptors which activate intracellular phos-
pholipases and release arachidonic acid. Since the release of
arachidonic acid from membrane phospholipids is a ¢nely
regulated process, which involves the activation of cPLA2,
these ¢ndings have been considered evidence of an e¡ect of
sPLA2-IIA on cPLA2 via a signaling cascade that mimics the
transducing mechanism conveyed by physiological activators
of cPLA2. Preliminary studies addressing these issues have
been conducted in both platelets and rat mesangial cells.
The studies in human platelets showed that sPLA2-IIA elicits
optical aggregation, generation of thromboxane A2, in£ux of
calcium ions, and time-dependent tyrosine phosphorylation of
several platelet proteins. These responses were abrogated by
pretreatment with both heparitinase and phosphatidylinositol-
speci¢c phospholipase C, thus suggesting that a glysophos-
phatidylinositol-anchored platelet-membrane heparan sulfate
proteoglycan is the binding site for sPLA2-IIA in human
platelets, and also that the engagement of this structure leads
to the release of the arachidonic acid needed for thromboxane
A2 production [31]. As regards mesangial cells, early studies
showing cross-talk between sPLA2-IIA and cPLA2 [32] have
been recently enlarged by the description of a synergistic e¡ect
of peroxisome proliferator-activated receptor and tumor ne-
crosis factor-K (TNF-K) on sPLA2-IIA expression [33], and by
the ¢nding that interleukin-1L enhances the expression of both
sPLA2-IIA and group V sPLA2 in rat mesangial cells [34],
thus pointing to the positive modulation of sPLA2-IIA expres-
sion as a relevant factor for kidney pathology.
The biological e¡ects of sPLA2-IIA have also been ad-
dressed in the astrocytoma cell line 1321N1, since this cell
line has a wide variety of surface receptors and responds to
many stimuli to which neurons are also responsive, thus mak-
ing it an adequate model for the study of signal transduction
pathways in the nervous system [35]. In this cell line, sPLA2-
IIA produces mobilization of Ca2þ from intracellular stores
by a mechanism involving the formation of inositol 1,4,5-tris-
phosphate from phosphatidylinositol bisphosphate by a phos-
pholipase CQ, which requires tyrosine phosphorylation reac-
tions and targeting to the membrane, thus involving a
phospholipase C subtype di¡erent from the L isoform that
is recruited by agonists acting through G protein-coupled re-
ceptors [36]. This was accompanied by the decrease in electro-
phoretic mobility (band-shift) that is characteristic of the
phosphorylation of cPLA2, and arachidonic acid release. Ac-
tivation of all of the modules of the MAP kinase family in-
volving p42-MAP/extracellular signal-regulated kinase (ERK)
kinase, c-Jun N-terminal kinase (JNK), and p38-MAP kinase
was also observed, as well as cell proliferation, as judged from
Table 1
E¡ect of sPLA2-IIA on astrocytoma cells and comparison with the actions of stimuli acting on other types of receptors
PLA2-IIA [37] Thrombin [53] Muscarinic M3 [54,56] TNF-R [55]
Activation of the Rel/NF-UB system 3 + 3 +
Mobilization of Ca2þ + + + 3
Activation of the ERK module of MAP kinase + + + 3
Activation of the stress module of MAP kinase + + 3 +
Proliferation/apoptosis Mitosis Mitosis Irrelevant Apoptosis
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an increased incorporation of [3H]thymidine into the tri-
chloroacetic acid-precipitable fraction of 1321N1 cells incuba-
ted in the presence of sPLA2-IIA (Table 1). Treatment with
the MAP kinase kinase of the MAP/ERK group (MEK) in-
hibitor PD-98059 inhibited the activation of both cPLA2 and
p42-MAP kinase, thus suggesting the coupling of cPLA2 to
the ERK pathway in response to sPLA2-IIA [37]. Fig. 1 sum-
marizes the signaling pathways engaged by sPLA2-IIA. These
responses show some overlap with those elicited by agonists
engaging G protein-coupled receptors as well as TNF-K re-
ceptors, but a number of di¡erences can be delineated.
3. sPLA2-IIA promotes pro-in£ammatory e¡ects and activates
Fas ligand in monocytic cells
Recent studies have suggested a role for sPLA2-IIA in the
pathogenesis of atherosclerosis on the basis of a series of ob-
servations, which support a role for this enzyme both on
plasma lipoproteins [38,39] and in the arterial wall [40^42].
In fact, circulating levels of sPLA2-IIA have been shown to
be sensitive predictors of coronary events in patients with
coronary arterial disease [43], and high amounts of sPLA2-
IIA have been found in human atherosclerotic arterial walls
and related to the development of atherosclerotic plaques [44].
As mentioned before, sPLA2-IIA has been found to associate
with decorin, a proteoglycan which forms part of the collagen
network in human arteries and links native low density lipo-
protein (LDL) to collagen [20]. Thus, sPLA2-IIA may con-
tribute to the pathogenesis of atherosclerosis by modifying
lipoproteins and releasing lipid mediators at places of lipopro-
tein retention in the arterial wall, as well as by inducing mi-
totic proliferation of human vascular smooth muscle cells [45].
In addition, mildly oxidized LDL induces expression of
sPLA2-IIA in human macrophages [46], and induction of
sPLA2-IIA expression is a characteristic of the di¡erentiation
of human arterial smooth muscle cells on exposure to inter-
feron-Q and other cytokines [47], thus pointing to the involve-
ment of sPLA2-IIA in the in£ammatory reaction of athero-
sclerosis. Attempts to disclose the biological e¡ects of sPLA2-
IIA in human macrophages have been carried out with
sPLA2-IIA at concentrations similar to those found in plasma
[48]. Under these conditions, sPLA2-IIA induced the produc-
tion of the monocyte chemoattractant chemokine monocyte
chemotactic protein-1 (MCP-1) and upregulated the surface
display of Fas ligand (Fig. 2B,C) without a¡ecting the distri-
bution of cells in the di¡erent phases of the cell cycle, thus
suggesting the upregulation of a juxtacrine mechanism of sig-
naling involving Fas ligand expressed and/or released on
monocytic cells and Fas expressed on other cells such as in-
¢ltrating leukocytes and endothelial cells. This ¢nding might
be of pathophysiological relevance in view of the increased
expression of sPLA2-IIA in clinical conditions such as athero-
sclerosis and rheumatoid arthritis [49], where the Fas-signal-
Fig. 1. Overview of signaling events coupled to the sPLA2 receptor
and connections with other receptors focusing on the results ob-
tained in 1321N1 astrocytoma cells and THP-1 monocytic cells. Up-
regulation of Fas ligand and synergism with TNF-K-mediated sig-
naling have been shown in THP-1 monocytic cells expressing
M-type sPLA2 receptor, whereas activation of the MAP kinase cas-
cade has also been reported in astrocytoma cells, mesangial cells
and mast cells. Activation of phospholipase CQ has been shown in
astrocytoma cells. The question mark placed in the sPLA2 receptor
indicates that these e¡ects have also been observed in cells lacking
the M-type receptor, for instance 1321N1 cells (Fig. 2A), thus chal-
lenging the notion that this structure is an absolute requirement for
these responses. AP-1, activation protein-1; IP3, inositol trisphos-
phate; Fas-L, Fas ligand; IUB, inhibitor of NF-UB; MKK, MAP
kinase kinase of the stress family of MAP kinase; MKKK, MAP
kinase kinase kinase; p38, p38 isoform of MAP kinase; PLCQ,
phospholipase CQ ; TNF-R, TNF receptor.
Fig. 2. E¡ect of sPLA2-IIA in cells expressing the M-type receptor
for sPLA2-IIA. Total mRNA was taken from 1321N1 astrocytoma
cells, THP-1 cells, and human monocytes and used for RT-PCR re-
actions using oligonucleotide primers designed from the human se-
quence of the sPLA2 M-type receptor. The expression of L-actin
was used as a control for the assay of a constitutively expressed
gene. PCR products were identi¢ed by automatic sequencing of the
DNA eluted from the agarose gel by excision of the band under
UV light followed by puri¢cation (A). The production of MCP-1 by
human monocytes incubated for 24 h in the presence of di¡erent
additions is shown in B. The e¡ect of sPLA2-IIA on the surface dis-
play of Fas ligand was addressed by £ow cytometry in human
monocytes adhered to plastic dishes and identi¢ed by the surface ex-
pression of CD11b (C). Taken from [48], with permission.
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ing pathway has been proposed to play a role in their patho-
genesis [50^52]. Since apoptosis mediated by Fas ligand re-
lease from mononuclear phagocytes is a mechanism of reso-
lution of in£ammation under non-phlogistic conditions, it is
possible to propose a programmed sequence of functions for
sPLA2-IIA on mononuclear phagocytes: (i) a set of pro-in-
£ammatory changes including activation of the MAP kinase
cascade, induction of cyclooxygenase-2, and mobilization of
monocytes; (ii) a contribution to the safe clearance of in¢l-
trating leukocytes through the triggering of the Fas/Fas ligand
system. Taken together, these ¢ndings enlarge the scope of
biological functions for sPLA2-IIA (Table 2) and stress the
variety of e¡ects elicited on di¡erent cell types.
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